Publications by authors named "Muhammad M Alhussein"
Article Synopsis
- The study explores using multi-phase Computed Tomography Angiography (mpCTA) for better assessing cardiac health before transcatheter aortic valve replacement (TAVR) and predicting patient outcomes.
- Researchers analyzed mpCTAs from 205 patients and found that 96% could be assessed, with specific deformation measurements indicating higher risks of complications like heart failure or death.
- The findings suggest that advanced 4D modeling techniques can predict outcomes post-TAVR effectively, and further validation in multiple centers is planned.
Aims: Epidemiological surveillance has raised safety concerns for mRNA SARS-CoV-2-vaccination-related myocarditis. We aimed to analyze epidemiological, clinical and imaging findings associated with clinical outcomes in these patients in an international multi-center registry (NCT05268458).
Methods And Results: Patients with clinical and CMR diagnosis of acute myocarditis within 30 days after mRNA SARS-CoV-2-vaccination were included from five centers in Canada and Germany between 05/21 and 01/22.
Background: Human epidermal growth factor receptor 2 (HER2) overexpressing malignancies, including breast and gastro-esophageal, are associated with a poor prognosis. The cardiotoxicity of trastuzumab, a HER2-targeting monoclonal antibody, is well established. However, the cardiotoxic effect of pertuzumab, another HER2-directed therapy, is less well documented.
View Article and Find Full Text PDFTrastuzumab is an effective treatment for HER2-positive breast cancer. Current guidelines recommend withholding trastuzumab in patients experiencing a significant asymptomatic decline in left ventricular function. In this commentary, we discuss the survival benefits afforded by trastuzumab juxtaposed against the risk of trastuzumab-mediated cardiotoxicity.
View Article and Find Full Text PDFObjectives: This study sought to evaluate the safety of continuing trastuzumab in patients with human epidermal growth factor receptor-positive breast cancer who developed mild cardiotoxicity.
Background: Cardiotoxicity is the most common dose-limiting toxicity associated with trastuzumab. Current standard of care is discontinuation of trastuzumab, which can lead to worse cancer outcomes.